AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more
AbbVie Inc - Asset Resilience Ratio
AbbVie Inc (ABBV) has an Asset Resilience Ratio of 0.02% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how AbbVie Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down AbbVie Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $28.00 Million | 0.02% |
| Total Liquid Assets | $28.00 Million | 0.02% |
Asset Resilience Insights
- Limited Liquidity: AbbVie Inc maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
AbbVie Inc Industry Peers by Asset Resilience Ratio
Compare AbbVie Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 14.06% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 5.03% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367 |
Drug Manufacturers - General | 32.14% |
Annual Asset Resilience Ratio for AbbVie Inc (2010–2025)
The table below shows the annual Asset Resilience Ratio data for AbbVie Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.02% | $28.00 Million | $133.96 Billion | 0.00pp |
| 2024-12-31 | 0.02% | $31.00 Million | $135.16 Billion | +0.02pp |
| 2023-12-31 | 0.00% | $2.00 Million | $134.71 Billion | -0.02pp |
| 2022-12-31 | 0.02% | $28.00 Million | $138.81 Billion | -0.04pp |
| 2021-12-31 | 0.06% | $84.00 Million | $146.53 Billion | +0.04pp |
| 2020-12-31 | 0.02% | $30.00 Million | $150.56 Billion | -- |
| 2019-12-31 | 0.00% | $0.00 | $89.11 Billion | -- |
| 2018-12-31 | 1.30% | $772.00 Million | $59.35 Billion | +0.61pp |
| 2017-12-31 | 0.69% | $486.00 Million | $70.79 Billion | -1.31pp |
| 2016-12-31 | 2.00% | $1.32 Billion | $66.10 Billion | +1.99pp |
| 2015-12-31 | 0.02% | $8.00 Million | $53.05 Billion | -0.08pp |
| 2014-12-31 | 0.09% | $26.00 Million | $27.51 Billion | -0.93pp |
| 2013-12-31 | 1.03% | $300.00 Million | $29.20 Billion | -6.66pp |
| 2012-12-31 | 7.68% | $2.08 Billion | $27.01 Billion | +4.48pp |
| 2011-12-31 | 3.21% | $626.00 Million | $19.52 Billion | +3.20pp |
| 2010-12-31 | 0.01% | $1.13 Million | $21.13 Billion | -- |